Candriam SCA’s AnaptysBio ANAB Stock Holding History

Candriam SCA’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,205	Closed	-$405K	–	725
2023 Q1	$405K	Buy	+20,205	New	+$491K	﹤0.01%	822
2020 Q2	–	Sell	-115,000	Closed	-$1.83M	–	806
2020 Q1	$1.83M	Hold	115,000	–	–	0.02%	543
2019 Q4	$1.87M	Buy	115,000 +65,000	+130%	+$1.54M	0.02%	559
2019 Q3	$1.75M	Sell	50,000 -20,000	-29%	-$952K	0.02%	518
2019 Q2	$3.93M	Hold	70,000	–	–	0.05%	383
2019 Q1	$5.11M	Hold	70,000	–	–	0.07%	321
2018 Q4	$4.46M	Hold	70,000	–	–	0.07%	303
2018 Q3	$6.98M	Buy	70,000 +35,900	+105%	+$2.98M	0.09%	253
2018 Q2	$2.42M	Buy	34,100 +7,100	+26%	+$596K	0.04%	443
2018 Q1	$2.81M	Sell	27,000 -12,500	-32%	-$1.41M	0.05%	406
2017 Q4	$3.98M	Buy	+39,500	New	+$2.91M	0.07%	315

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA's ANAB Position: Q2 2023 in Review

Candriam SCA sold out of AnaptysBio (ANAB) in Q2 2023, closing a stake of 20,205 shares — an estimated $405K sold.

Candriam SCA first reported a position in ANAB in Q4 2017 and held it in 11 quarters. The position peaked at $6.98M in Q3 2018. 116 funds tracked by Wall St. Rank hold ANAB as of Q2 2023.

Candriam SCA reported no remaining AnaptysBio position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 20,205 AnaptysBio shares in Q2 2023, an estimated $405K.
Candriam SCA first reported a position in AnaptysBio in Q4 2017 and held it in 11 quarters.
Candriam SCA's AnaptysBio position peaked at $6.98M in Q3 2018.
116 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.